PEIJIA-B's revenue for the first half of the year was approximately 350-360 million yuan, a year-on-year increase of about 16.2%-19.5%
PEIJIA-B announced that its revenue for the first half of 2025 is expected to be approximately RMB 350 million to RMB 360 million, representing a year-on-year growth of about 16.2% to 19.5%. The revenue growth is mainly attributed to the expansion of its market share in China's TAVR market, the launch of high-end product offerings, and strong performance of key neurointerventional products. During the reporting period, the total number of TAVR implants exceeded 2,050, a year-on-year increase of approximately 18.8%
According to the Zhitong Finance APP, PEIJIA-B (09996) announced that the group's revenue for the first half of 2025 is expected to be approximately 350 million to 360 million yuan, representing a year-on-year growth of about 16.2% to 19.5%.
The announcement stated that the main drivers of revenue growth are as follows: the group's market share in the transcatheter aortic valve replacement (TAVR) market in China has further expanded, and the product portfolio has shifted towards newly launched high-end products; strong performance of key neuro-interventional products, such as increased market penetration of existing leading products like the DCwire® microcatheter, Tethys AS® thrombectomy catheter, and Fastunnel® delivery balloon catheter; and the successful launch of the newly approved YonFlow® blood flow-directed stent.
During the reporting period, the group's comprehensive TAVR portfolio (including TaurusOne®, TaurusElite®, and the newly launched TaurusMax®) expanded to over 70 new medical institutions, covering more than 720 medical institutions as of June 30, 2025. The total number of TAVR implants during the reporting period exceeded 2,050, representing a year-on-year growth of approximately 18.8%
